Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended open-label brexpiprazole treatment for agitation in Alzheimer's dementia (Japan)
jRCT2080224118Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole in Alzheimer's disease (AD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Safety over 14-week extension. Started Oct 2018; status: completed.
02
Drugs
brexpiprazole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080224118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224118.